Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SER-AP-ES vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Reserpine: 50-100h (terminal); hydralazine: 2-8h (slow acetylators 4-8h, fast 2-4h); hydrochlorothiazide: 6-15h. Context: reserpine's long t½ accounts for prolonged effects; hydralazine requires dose adjustment for acetylator status.
3â6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Reserpine: extensively metabolized in liver; Hydralazine: hepatic acetylation (N-acetyltransferase); Hydrochlorothiazide: not metabolized, excreted unchanged.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 30-40% unchanged reserpine; 60-70% as metabolites (hydralazine: 50% renal, 15% fecal; hydrochlorothiazide: 95% renal unchanged).
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Reserpine: 40% bound (albumin); hydralazine: 87% bound; hydrochlorothiazide: 40-68% bound (albumin).
~20% bound to albumin; minimal binding to other plasma proteins.
Reserpine: 6 L/kg; hydralazine: 1.6 L/kg; hydrochlorothiazide: 0.8 L/kg. Clinical meaning: reserpine extensive tissue distribution (fat, brain); hydralazine moderate; thiazide limited to extracellular fluid.
0.2â0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Reserpine: 50% oral; hydralazine: 30-50% oral; hydrochlorothiazide: 65-75% oral.
Oral: 30â40% (due to extensive first-pass metabolism); IV: 100%.
Hydrochlorothiazide: Contraindicated if Cr Cl < 30 m L/min. For Cr Cl 30-50 m L/min: reduce dose of hydrochlorothiazide to 12.5 mg daily; consider using individual components. Reserpine and hydralazine: no specific GFR-based adjustment, but use with caution if severe renal impairment.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Reserpine and hydralazine are contraindicated in severe hepatic impairment. For Child-Pugh A or B: no specific dose adjustment but monitor closely. For Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for pediatric use due to lack of safety and efficacy data. Use individual components with appropriate weight-based dosing if needed.
Not recommended; inadequate safety data.
Initiate with one tablet orally once daily. Titrate slowly due to increased risk of hypotension, electrolyte disturbances, and central nervous system effects. Monitor renal function and electrolytes closely.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Reserpine: May cause depression, peptic ulcer activation.,Hydralazine: Drug-induced lupus, peripheral neuritis (pyridoxine deficiency), tachycardia.,Hydrochlorothiazide: Electrolyte imbalance, hyperuricemia, photosensitivity.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to any component,History of depression (reserpine),Severe renal impairment (hydralazine, hydrochlorothiazide),Anuria (hydrochlorothiazide)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid foods high in sodium to prevent bloating and counteract diuretic effect. Excessive potassium intake (e.g., salt substitutes, bananas, oranges) may be needed if hypokalemia is present, but monitor potassium levels. Grapefruit juice may alter absorption; avoid large amounts. Alcohol increases risk of hypotension and sedation; avoid concurrent use.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
SER-AP-ES is a combination product containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine: crosses placenta, animal studies show fetal abnormalities (skeletal and CNS) in high doses; first trimester risk uncertain, second/third trimester associated with neonatal respiratory depression, bradycardia, hypothermia. Hydralazine: animal studies show cleft palate, skeletal malformations; human data limited; risk not excluded. Hydrochlorothiazide: associated with neonatal thrombocytopenia, electrolyte disturbances, and possibly fetal or neonatal jaundice; second/third trimester use may cause fetal hypoxia and placental insufficiency. Overall, avoid in pregnancy unless benefit outweighs risk; first trimester highest risk.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine: excreted into breast milk; M/P ratio ~0.5; may cause galactorrhea, breast engorgement, or adverse effects in infant (drowsiness, nasal congestion). Hydralazine: present in breast milk in low amounts (M/P ratio ~1); considered compatible but monitor infant for hypotension. Hydrochlorothiazide: excreted in breast milk in low concentrations (M/P ratio ~0.5); may suppress lactation and cause electrolyte imbalance in infant. Use caution; avoid if possible or monitor infant.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pharmacokinetic changes: increased plasma volume and renal clearance may reduce drug concentrations; hydralazine undergoes acetylation (polymorphic), may require dose increase. Reserpine: no data, but similar adjustments not typically recommended. Hydrochlorothiazide: reduced efficacy due to volume expansion; avoid in pregnancy-induced hypertension. In severe hypertension, hydralazine may be used IV with cautious titration; oral adjustments: start low, titrate based on response.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
SER-AP-ES is a combination antihypertensive containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine depletes catecholamines centrally and peripherally; may cause depression, nasal congestion, and bradycardia. Hydralazine is a direct vasodilator; can cause drug-induced lupus-like syndrome, especially in slow acetylators. Hydrochlorothiazide is a thiazide diuretic; monitor for hypokalemia, hyponatremia, and hyperglycemia. Avoid use in patients with depression, peptic ulcer disease, or history of SLE. Titrate slowly due to reserpine's cumulative effect.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed; do not stop suddenly as this may cause rapid rise in blood pressure.,Avoid over-the-counter cold or allergy medications without consulting your doctor.,Report symptoms of depression, mood changes, or suicidal thoughts immediately.,May cause dizziness or drowsiness; avoid driving until you know how this medication affects you.,Do not consume alcohol; it may increase side effects.,Monitor your blood pressure regularly and keep a log.,Stay hydrated but avoid excessive salt intake.,Report any unexplained fever, joint pain, or skin rash; may be signs of lupus-like reaction.,This medication may increase blood sugar; monitor if diabetic.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SER-AP-ES vs ALDORIL D50, answered by our medical review team.
SER-AP-ES is a Antihypertensive Combination that works by SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SER-AP-ES and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SER-AP-ES is: SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SER-AP-ES and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SER-AP-ES is classified as Category C. SER-AP-ES is a combination product containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine: crosses placenta, animal studies show fetal abnormalities (skeletal and CN. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.